These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 31961918)
1. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918 [No Abstract] [Full Text] [Related]
2. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Abramson JS; Lunning M; Palomba ML Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671 [TBL] [Abstract][Full Text] [Related]
3. Updates on CAR T-cell therapy in B-cell malignancies. Jacoby E; Shahani SA; Shah NN Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474 [TBL] [Abstract][Full Text] [Related]
5. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821 [TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases. Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847 [TBL] [Abstract][Full Text] [Related]
7. Challenges of driving CD30-directed CAR-T cells to the clinic. Grover NS; Savoldo B BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880 [TBL] [Abstract][Full Text] [Related]
8. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819 [TBL] [Abstract][Full Text] [Related]
9. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083 [TBL] [Abstract][Full Text] [Related]
10. Managing the toxicities of CAR T-cell therapy. Neelapu SS Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of failure of chimeric antigen receptor T-cell therapy. Li X; Chen W Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606 [TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Strati P; Neelapu SS Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158 [TBL] [Abstract][Full Text] [Related]
14. Impact of Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572 [TBL] [Abstract][Full Text] [Related]
15. Recent updates on CAR T clinical trials for multiple myeloma. Lin Q; Zhao J; Song Y; Liu D Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964 [TBL] [Abstract][Full Text] [Related]
16. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647 [TBL] [Abstract][Full Text] [Related]
17. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. Sharma P; King GT; Shinde SS; Purev E; Jimeno A Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253 [TBL] [Abstract][Full Text] [Related]
18. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System. Chicaybam L; Abdo L; Bonamino MH Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672 [TBL] [Abstract][Full Text] [Related]
19. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond. Quintás-Cardama A Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790 [No Abstract] [Full Text] [Related]
20. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Abramson JS Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]